<DOC>
	<DOC>NCT00710684</DOC>
	<brief_summary>The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.</brief_summary>
	<brief_title>A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Subjects and their caregivers must provide informed consent prior to study entry. Subjects must have a clinical diagnosis of probable mildtomoderate Alzheimer's disease with no evidence of disorders that are thought to be the cause of, or contributing to the severity of the subject's dementia and a documented history of at least 6 months of ongoing donepezil therapy with stable dosing for at least the last 2 months. Subjects must have a regular caregiver who is willing to attend visits, oversee the subject's compliance with the study and report on the subject's status. Female subjects of childbearing potential must agree to abstinence or an approved form of birth control. Subjects must have adequate blood pressure and laboratory values. Subjects with a diagnosis of possible, probable or definite vascular dementia may not participate. Subjects with known hypersensitivity to sunlight or a history of seizures, previous exposure to SB742457, taking agents for which there is a theoretical risk of interaction with SB742457, or taking medication for Alzheimer's disease or centrally acting agents which might impact study outcomes may not participate.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Alzheimer's disease cognition SB-742457</keyword>
</DOC>